SPA
ACAD icon

Sherbrooke Park Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Sherbrooke Park Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,638
Closed -$415K – 568
2024
Q4 		$415K Buy
22,638
+4,172
+23% +$67.3K 0.13% 277
2024
Q3 		$284K Sell
18,466
-4,406
-19% -$73.5K 0.07% 589
2024
Q2 		$372K Sell
22,872
-12,528
-35% -$202K 0.07% 535
2024
Q1 		$655K Buy
+35,400
New +$877K 0.13% 275

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Sherbrooke Park Advisers's ACAD Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 22,638 shares — an estimated $415K sold.

Sherbrooke Park Advisers first reported a position in ACAD in Q1 2024 and held it in 4 quarters. The position peaked at $655K in Q1 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 22,638 Acadia Pharmaceuticals shares in Q1 2025, an estimated $415K.
  • Sherbrooke Park Advisers first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Acadia Pharmaceuticals position peaked at $655K in Q1 2024.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.